These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21310613)

  • 1. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer.
    Dong Q; Dougan DR; Gong X; Halkowycz P; Jin B; Kanouni T; O'Connell SM; Scorah N; Shi L; Wallace MB; Zhou F
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1315-9. PubMed ID: 21310613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR.
    Le PT; Cheng H; Ninkovic S; Plewe M; Huang X; Wang H; Bagrodia S; Sun S; Knighton DR; LaFleur Rogers CM; Pannifer A; Greasley S; Dalvie D; Zhang E
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5098-103. PubMed ID: 22749419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors.
    Wallace MB; Adams ME; Kanouni T; Mol CD; Dougan DR; Feher VA; O'Connell SM; Shi L; Halkowycz P; Dong Q
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4156-8. PubMed ID: 20621728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.
    Lieu CH; Klauck PJ; Henthorn PK; Tentler JJ; Tan AC; Spreafico A; Selby HM; Britt BC; Bagby SM; Arcaroli JJ; Messersmith WA; Pitts TM; Eckhardt SG
    Oncotarget; 2015 Oct; 6(33):34561-72. PubMed ID: 26439693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.
    Isshiki Y; Kohchi Y; Iikura H; Matsubara Y; Asoh K; Murata T; Kohchi M; Mizuguchi E; Tsujii S; Hattori K; Miura T; Yoshimura Y; Aida S; Miwa M; Saitoh R; Murao N; Okabe H; Belunis C; Janson C; Lukacs C; Schück V; Shimma N
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1795-801. PubMed ID: 21316218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
    Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
    Erlanson DA; Arndt JW; Cancilla MT; Cao K; Elling RA; English N; Friedman J; Hansen SK; Hession C; Joseph I; Kumaravel G; Lee WC; Lind KE; McDowell RS; Miatkowski K; Nguyen C; Nguyen TB; Park S; Pathan N; Penny DM; Romanowski MJ; Scott D; Silvian L; Simmons RL; Tangonan BT; Yang W; Sun L
    Bioorg Med Chem Lett; 2011 May; 21(10):3078-83. PubMed ID: 21459573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy.
    Adams ME; Wallace MB; Kanouni T; Scorah N; O'Connell SM; Miyake H; Shi L; Halkowycz P; Zhang L; Dong Q
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2411-4. PubMed ID: 22406151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An efficient route for the synthesis of a new class of pyrido[2,3-d]pyrimidine derivatives.
    Tu S; Zhang J; Jia R; Jiang B; Zhang Y; Jiang H
    Org Biomol Chem; 2007 May; 5(9):1450-3. PubMed ID: 17464415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trametinib.
    Zeiser R
    Recent Results Cancer Res; 2014; 201():241-8. PubMed ID: 24756797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3β inhibitors.
    Coffman K; Brodney M; Cook J; Lanyon L; Pandit J; Sakya S; Schachter J; Tseng-Lovering E; Wessel M
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1429-33. PubMed ID: 21295469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.
    Ren L; Ahrendt KA; Grina J; Laird ER; Buckmelter AJ; Hansen JD; Newhouse B; Moreno D; Wenglowsky S; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Risom T; Sturgis HL; Voegtli WC; Mathieu S
    Bioorg Med Chem Lett; 2012 May; 22(10):3387-91. PubMed ID: 22534450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C; Settleman J
    Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
    Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
    J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors.
    Pasquier B; El-Ahmad Y; Filoche-Rommé B; Dureuil C; Fassy F; Abecassis PY; Mathieu M; Bertrand T; Benard T; Barrière C; El Batti S; Letallec JP; Sonnefraud V; Brollo M; Delbarre L; Loyau V; Pilorge F; Bertin L; Richepin P; Arigon J; Labrosse JR; Clément J; Durand F; Combet R; Perraut P; Leroy V; Gay F; Lefrançois D; Bretin F; Marquette JP; Michot N; Caron A; Castell C; Schio L; McCort G; Goulaouic H; Garcia-Echeverria C; Ronan B
    J Med Chem; 2015 Jan; 58(1):376-400. PubMed ID: 25402320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
    Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
    Wittman M; Carboni J; Attar R; Balasubramanian B; Balimane P; Brassil P; Beaulieu F; Chang C; Clarke W; Dell J; Eummer J; Frennesson D; Gottardis M; Greer A; Hansel S; Hurlburt W; Jacobson B; Krishnananthan S; Lee FY; Li A; Lin TA; Liu P; Ouellet C; Sang X; Saulnier MG; Stoffan K; Sun Y; Velaparthi U; Wong H; Yang Z; Zimmermann K; Zoeckler M; Vyas D
    J Med Chem; 2005 Sep; 48(18):5639-43. PubMed ID: 16134929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects for MEK inhibitors for treating cancer.
    Martin-Liberal J; Lagares-Tena L; Larkin J
    Expert Opin Drug Saf; 2014 Apr; 13(4):483-95. PubMed ID: 24597490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.
    Goldstein DM; Soth M; Gabriel T; Dewdney N; Kuglstatter A; Arzeno H; Chen J; Bingenheimer W; Dalrymple SA; Dunn J; Farrell R; Frauchiger S; La Fargue J; Ghate M; Graves B; Hill RJ; Li F; Litman R; Loe B; McIntosh J; McWeeney D; Papp E; Park J; Reese HF; Roberts RT; Rotstein D; San Pablo B; Sarma K; Stahl M; Sung ML; Suttman RT; Sjogren EB; Tan Y; Trejo A; Welch M; Weller P; Wong BR; Zecic H
    J Med Chem; 2011 Apr; 54(7):2255-65. PubMed ID: 21375264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.